Business Watch: Solstice, Element cancel deal; FDA approves daraxonrasib for pancreatic cancer
Sep 1, 2026
Solstice Advanced Materials canceled its acquisition of Element Solutions due to shareholder concerns, amidst mixed M&A sentiment in the chemical sector including the Olin-Huntsman merger. The FDA also approved daraxonrasib for pancreatic cancer treatment.